Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials

The scenario of neoadjuvant and adjuvant settings in non-small cell lung cancer (NSCLC) is rapidly evolving. As already happened for the advanced disease, also early stages have entered the era of precision medicine, with molecular analysis and Programmed death-ligand 1 (PD-L1) evaluation that by no...

Descripción completa

Detalles Bibliográficos
Autores principales: de Scordilli, Marco, Michelotti, Anna, Bertoli, Elisa, De Carlo, Elisa, Del Conte, Alessandro, Bearz, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266864/
https://www.ncbi.nlm.nih.gov/pubmed/35806230
http://dx.doi.org/10.3390/ijms23137222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266864/
https://www.ncbi.nlm.nih.gov/pubmed/35806230
http://dx.doi.org/10.3390/ijms23137222

Ejemplares similares